ZUG, Switzerland — October 8, 2026
Galderma announced new long-term data for Nemluvio (nemolizumab) demonstrating sustained improvements in skin lesions and itch among adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis. The findings, scheduled for presentation at the 2026 Fall Clinical Dermatology Conference in Las Vegas, include a post-hoc analysis from the ARCADIA long-term extension (LTE) study. Among patients who responded to treatment at Week 16, the majority maintained substantial improvements in skin clearance and itch through three years. The results add to the growing clinical evidence supporting Nemluvio’s long-term treatment potential in atopic dermatitis and prurigo nodularis.
ARCADIA Analysis Highlights Durable Treatment Responses
The post-hoc analysis evaluated 295 patients who achieved a clinical response at Week 16 in the ARCADIA trials and continued treatment during the maintenance and long-term extension phases. At Week 152, 76% achieved clear or almost-clear skin, while 80% achieved at least a 90% improvement in eczema severity, measured by the Eczema Area and Severity Index (EASI-90). Half of the patients achieved complete skin clearance, defined as EASI-100, and 80% reached an itch-free or nearly itch-free state. These findings suggest that early responders may maintain meaningful improvements with continued treatment. Galderma reported that Nemluvio remained well tolerated, with no new safety signals identified in the analysis.
Long-Term Findings Extend Across Dermatology Indications
A separate interim analysis of the overall ARCADIA LTE population assessed 1,903 adults and adolescents with moderate-to-severe atopic dermatitis through Week 152. Based on observed-case analyses, up to 91% achieved EASI-75, up to 75% achieved EASI-90 and up to 67% had clear or almost-clear skin. Up to 88% experienced clinically meaningful itch relief, while up to 73% achieved an itch-free or nearly itch-free state. Up to 92% reported clinically meaningful improvements in dermatology-related quality of life. Galderma will also present data from a Phase II pediatric study in children aged two to 11 years, showing improvements in skin lesions and itch through Week 16 that were sustained through Week 52. Nemluvio’s safety profile remained consistent with previous findings across the reported analyses.
Advertisement
Nemluvio Development Advances in Atopic Dermatitis and Prurigo Nodularis
Additional findings from the OLYMPIA long-term extension study showed sustained improvements in the burden of prurigo nodularis through Week 148, including itch, pain, sleep disturbance and quality of life. At Week 48, more than 85% of patients achieved clinically meaningful itch improvement, approximately three-quarters were itch-free or nearly itch-free, and 60% reported no disease-associated pain. Galderma also highlighted improvements in sleep and dermatology-related quality of life. Nemluvio is a monoclonal antibody that targets signaling through the interleukin-31 (IL-31) receptor pathway, which is involved in itch and inflammation. In the United States, it is approved for adults with prurigo nodularis and for patients aged 12 years and older with moderate-to-severe atopic dermatitis in combination with topical prescription therapies when those treatments do not adequately control the disease. The newly presented long-term and pediatric findings further inform its ongoing clinical use and development.
Source::Galderma, press release
